<DOC>
	<DOCNO>NCT02046369</DOCNO>
	<brief_summary>A study evaluate efficacy safety flexibly dose Lurasidone child adolescents bipolar I depression</brief_summary>
	<brief_title>Lurasidone Pediatric Bipolar Study</brief_title>
	<detailed_description>This randomize , parallel , double-blind , placebo-controlled study design evaluate efficacy safety flexibly dose lurasidone ( 20 - 80 mg/day ) 6 week compare placebo child adolescent subject depression associate Bipolar I Disorder ( bipolar depression ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Written inform consent parent ( ) legal guardian ( ) sufficient intellectual capacity understand study support subject ' adherence study procedure must obtain subject emancipate . If emancipate , subject must provide write informed consent . In accordance Institutional Review Board ( IRB ) requirement , subject complete inform assent prior study participation . Male female subject 10 17 year age , inclusive bipolar I disorder , recent episode depress , without rapid cycle disease course ( ≥ 4 episode mood disturbance &lt; 8 episode previous 12 month ) without psychotic feature ( diagnose DSMV criterion , confirmation bipolar I disorder diagnosis adequately trained clinician time screening , mean Schedule Affective Disorders Schizophrenia Schoolage Children [ KSADSPL ] ) . Note : The current episode major depression associate bipolar I disorder must confirm investigator note source record . Subject lifetime history least one manic episode . A reliable informant ( eg , family member caregiver ) medical record must able confirm history . Subject 's current major depressive episode ≥ 4 week less 12 month duration . CDRSR score ≥ 45 screen Baseline . YMRS score ≤ 15 ( YMRS Item 1 [ elevate mood ] score ≤ 2 ) screen Baseline . Within 3rd 97th percentile gender specific BMIforage growth chart World Health Organization ( WHO ) growth chart In good physical health basis medical history , physical examination , laboratory screening . Females participate study : unable become pregnant ( eg , premenarchal , surgically sterile , etc . ) OR practice true abstinence ( consistent lifestyle ) must agree remain abstinent signing informed consent least 7 day last dose study drug take ; OR sexually active willing use medically effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . Males must willing remain sexually abstinent ( consistent lifestyle ) use effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . In judgment investigator , subject able swallow size number study drug tablet specify per protocol Willing able adhere protocolspecified meal requirement dose . Subjects may lifetime diagnosis ADHD . If subject take psychostimulants ADHD , must stable treatment regimen medication ( ) 30 day prior screen treatment regimen expect remain stable throughout study . This must confirm investigator note source record . Has Axis I Axis II ( DSMIV DSM5 ) diagnosis bipolar I disorder primary focus treatment within 3 month screen . Subject hospitalize bipolar manic mixed episode within 30 day prior randomization . Has history current diagnosis intellectual disability , autism spectrum disorder , neuroleptic malignant syndrome , neurologic disorder , severe head trauma . Lifetime history human immunodeficiency virus ( HIV ) positive acquire immune deficiency syndrome ( AIDS ) , history Hepatitis B C. Any following : Documented history chromosomal disorder developmental impairment ( ie , trisomy chromosome 21 ; 22q11 deletion syndrome ) . Evidence chronic organic disease CNS tumor , inflammation , active seizure disorder , vascular disorder , potential CNS relate disorder might occur childhood eg , Duchenne muscular dystrophy , myasthenia gravis , neurologic serious neuromuscular disorder . In addition , subject must history persistent neurological symptom attributable serious head injury . Past history febrile seizure , druginduced seizure , alcohol withdrawal seizure exclusionary . CDRSR total score &gt; 85 screen Baseline Demonstrates decrease ( improvement ) ≥ 25 % CDRSR adjust total score Screening Baseline visit , CDRSR 45 Baseline . Exhibits evidence moderate severe extrapyramidal symptom , dystonia , tardive dyskinesia , moderate severe movement disorder . Severity determine investigator . Lifetime history electroconvulsive therapy ( ECT ) . Resistant antipsychotic treatment base least two prior adequate trial ( ie , adequate dose duration ) antipsychotic agent within current episode depression , subject history nonresponse adequate ( 6week ) trial three antidepressant ( without mood stabilizer ) current episode . Clinically significant neurological , metabolic ( include Type 1 diabetes ) , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , carcinoma , and/or urological disorder would pose risk subject participate study might confound result study . Has history malignancy &lt; 5 year prior sign inform consent . Clinically significant finding ( ) physical examination determine investigator pose health concern subject study . Clinically relevant abnormal laboratory value abnormal vital sign values/findings . A history presence abnormal ECG , investigator 's opinion clinically significant . Abnormal screen ECGs centrally overread , eligibility determine base overread . Presence history ( within last year ) medical surgical condition ( eg , gastrointestinal disease ) might interfere absorption , metabolism , excretion orally administer lurasidone . Clinically significant substance abuse disorder ( exception caffeine tobacco ) base DSM5 criterion within last 6 month prior screen . Positive test result screen Baseline : 1 . Urine drug abuse ( include amphetamines/methamphetamines , barbiturate , benzodiazepine , cocaine , opioids , phencyclidine , cannabinoids ) . A positive test amphetamines/methamphetamines , barbiturate , opioids , benzodiazepine may result exclusion subject investigator determines positive test result take prescription medicine ( ) prescribe . In event subject test positive cannabinoids ( tetrahydrocannabinol ) , investigator evaluate subject 's ability abstain prohibit substance study . If investigator 's clinical judgment subject abstain , subject may enrol consultation Medical Monitor . 2 . Pregnancy test . Females pregnant , lactating , likely become pregnant study . Participated another interventional clinical trial receive investigational product within 30 day prior screen . Donation whole blood within 60 day prior randomization . Known history presence clinically significant intolerance antipsychotic medication include limited angioedema , serotonin neuroleptic malignant syndrome . Clinically relevant history drug hypersensitivity lurasidone component formulation . Use concomitant medication consistently prolong QT/QTc interval within 28 day prior randomization . Received depot neuroleptic unless last injection least 1 month 1 treatment cycle prior screening , whichever longer . Received treatment antidepressant , atomoxetine alpha 2 agonist ( eg , guanfacine ) within 3 day prior randomization , fluoxetine hydrochloride within 21 day randomization , monoamine oxidase ( MAO ) inhibitor within 28 day randomization , clozapine within 120 day randomization . Use psychotropic medication prior randomization exception medication explicitly permit within 3 day prior randomization ( 7 day prior randomization aripiprazole ) . Has prolactin concentration ≥ 100 ng/mL screening , history pituitary adenoma . At screen Baseline subject answer `` yes '' `` Suicidal Ideation '' Items 4 5 CSSRS score 7 item 13 , Suicidal Ideation , CDRSR . Subject consider investigator imminent risk suicide injury self , others , property study . Subject history one serious suicide attempt ( base investigator 's judgment ) 3 month prior screen . Subjects determine risk suicide injury , assess investigator screening , refer psychiatric evaluation . Adhering special diet 28 day prior drug administration ( eg , liquid , protein , raw food diet ) . Subject plan move study , chronically homeless , unable attend plan study visit . The Medical Monitor consult individual case , need . Subject newly diagnose Type 2 diabetes screen subject injectable medication treatment Type 2 diabetes . A subject Type 2 diabetes eligible study inclusion consider clinically stable , define : Random ( nonfasting ) screen glucose &lt; 200 mg/dl ( 11.1 mmol/L ) ; If ≥ 200 mg/dL ( 11.1 mmol/L ) must retested fasted state . Retested fasted value ≥ 126 mg/dL . HbA1c ≤ 6.5 % ; If subject currently treat oral antidiabetic medication ( ) , dose must stable least 4 week prior screen . Such medication may adjust discontinue study , clinically indicate . Subject require hospitalization diabetes related complication past 12 month . The use concomitant medication potent inducer inhibitor cytochrome P450 ( CYP ) 3A4 enzyme system trial ( sign inform consent followup ) . Clinically significant orthostatic hypotension ( ie , drop systolic blood pressure 20 mmHg and/or drop diastolic blood pressure 10 mmHg within 4 minute stand ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lurasidone , Latuda , Bipolar Depression</keyword>
</DOC>